home
Number
Title
Author
Date
123
HLB set to apply for conditional domestic approval of rivoceranib
admin
2022.11.09
122
HLB completes preparatory meeting with FDA for approval of liver cancer drug
admin
2022.10.14
121
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
admin
2022.10.13
120
Clinical Trial Results Allude to New Options for Patients With HCC
admin
2022.10.07
119
Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
admin
2022.10.07
118
Novel CAR-T therapies from HLB and GC Cell’s US affiliates take spotlight
admin
2022.09.27
117
HLB drug candidate shows longest liver cancer survival duration
admin
2022.09.14
116
Domestic expert positively evaluates rivoceranib’s phase 3 clinical results
admin
2022.09.13
115
HLB’s anticancer drug candidate shows world’s longest survival duration against liver cancer
admin
2022.09.08
114
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression
admin
2022.09.08